| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | NEUTRAL | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.27▼ | 4.34▼ | 4.37▼ | 4.06▲ | 3.67▲ |
| MA10 | 4.30▼ | 4.39▼ | 4.29▼ | 4.10▲ | 3.64▲ |
| MA20 | 4.33▼ | 4.28▼ | 4.18▲ | 3.77▲ | 3.75▲ |
| MA50 | 4.39▼ | 4.17▲ | 4.01▲ | 3.69▲ | 3.44▲ |
| MA100 | 4.31▼ | 4.05▲ | 3.94▲ | 3.74▲ | 11.36▼ |
| MA200 | 4.19▲ | 3.90▲ | 3.62▲ | 3.25▲ | 24.30▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.005▼ | -0.014▼ | 0.012▲ | 0.051▲ | 0.112▲ |
| RSI | 37.163▼ | 50.191▲ | 55.260▲ | 58.724▲ | 54.407▲ |
| STOCH | 21.818 | 42.382 | 72.833 | 41.165 | 42.954 |
| WILL %R | -83.333▼ | -62.338 | -42.105 | -34.810 | -27.500 |
| CCI | -56.951 | -70.287 | 29.516 | 79.656 | 96.958 |
|
Tuesday, March 17, 2026 07:30 AM
X4 Pharmaceuticals (NASDAQ: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the fourth quarter and year ended December 31, ...
|
|
Tuesday, March 17, 2026 04:45 AM
Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for ...
|
|
Monday, March 09, 2026 03:15 PM
Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 20/03/26 | 4.14 | 4.495 | 4.10 | 4.28 | 643,418 |
| 19/03/26 | 4.01 | 4.175 | 3.92 | 4.17 | 259,000 |
| 18/03/26 | 4.16 | 4.42 | 3.98 | 4.05 | 557,724 |
| 17/03/26 | 3.75 | 4.23 | 3.6291 | 4.23 | 614,008 |
| 16/03/26 | 3.64 | 3.695 | 3.53 | 3.56 | 442,049 |
| 13/03/26 | 3.88 | 4.05 | 3.68 | 3.69 | 216,936 |
| 12/03/26 | 4.27 | 4.27 | 3.87 | 3.88 | 308,374 |
| 11/03/26 | 4.63 | 4.67 | 4.31 | 4.33 | 610,375 |
| 10/03/26 | 4.21 | 4.83 | 4.21 | 4.66 | 1,989,878 |
| 09/03/26 | 3.72 | 4.16 | 3.72 | 4.15 | 589,951 |
|
|
||||
|
|
||||
|
|